Wegovy Tablets for Weight Loss | From £95 | Oral Semaglutide

Wegovy tablets contain semaglutide, a medicine that works by mimicking GLP-1 — a hormone your body naturally produces after eating. GLP-1 signals to your brain that you're full, slows how quickly food leaves your stomach, and reduces the urge to keep eating.

For people living with obesity or excess weight, this system often doesn't function as it should. Semaglutide restores those fullness signals, making it easier to eat less, feel satisfied with smaller meals, and cut through persistent food cravings.

What makes the tablet possible is a delivery ingredient called SNAC. It protects semaglutide from being broken down in the stomach, allowing it to be absorbed directly through the stomach lining. This is what makes a once-daily oral GLP-1 treatment viable at a dose proven to support meaningful weight loss.

Read More

The OASIS 4 clinical trial — published in the New England Journal of Medicine in 2025 — followed adults with overweight or obesity for 71 weeks. All participants received lifestyle support alongside treatment.

Someone starting at 16 stone would lose around 2 stone 2 pounds on average. More than half of participants also reported that everyday physical activities felt easier by the end of the trial.

Beyond weight, the trial recorded improvements in waist size, blood fats, blood pressure, and blood sugar levels. Over 7 in 10 people who had prediabetes at the start of the study had normal blood sugar readings by week 64.

Source: Wharton S, et al. N Engl J Med 2025;393:1077–1087 (OASIS 4). Le Roux CW, et al. OASIS 4 secondary analysis. ECO 2026.

Read More

Both contain semaglutide and work through the same mechanism. The difference is how they're delivered — and for many patients, that's the whole point.

The injection produces slightly higher average weight loss overall, but Wegovy tablets show a higher proportion of patients losing 20% or more. For anyone who prefers not to inject, the tablet is a clinically meaningful option — not a lesser one.

Tablet data: OASIS 4 (Wharton et al, NEJM 2025). Injection data: STEP 1 (Wilding et al, NEJM 2021). Cross-trial comparisons should be interpreted with caution.

Wegovy tablets offer a needle-free GLP-1 option with clinically meaningful weight loss results. Below is a summary comparison with other commonly prescribed weight loss treatments available in the UK.

Cross-trial comparisons should be interpreted with caution. Sources: OASIS 4, SURMOUNT-1, COR programme trials, NICE TA875/TA664.

Wegovy tablets come in four strengths: 1.5mg, 4mg, 9mg, and 25mg. Treatment starts at the lowest dose and increases every 30 days, giving your body time to adjust and reducing the chance of side effects.

How to take each dose

• Take once every morning on an empty stomach
• Swallow whole with no more than 100ml of water — more than this reduces absorption
• Do not chew, split, or dissolve the tablet
• Wait at least 30 minutes before eating, drinking (anything other than water), or taking other medicines

Yes. Because the tablet and injection are absorbed differently, switching requires prescriber guidance rather than a straightforward dose-for-dose swap. The general approach is to restart the titration schedule from the lowest dose (1.5mg), with your prescriber advising on the most appropriate starting point for your circumstances.

Please note: There is no officially published UK switching protocol. The guidance above is based on clinical principles only. Always consult your prescriber before making any changes to your treatment.

Wegovy tablets are prescribed for adults who meet at least one of the following criteria:

Standard eligibility

• BMI of 30 or above, or
• BMI of 27 or above with a weight-related health condition (such as high blood pressure, high cholesterol, or type 2 diabetes)

Read More

Minority ethnic backgrounds

Clinical guidelines recognise that people from certain minority ethnic groups carry a higher risk of weight-related conditions at a lower BMI. For these patients, the thresholds are:

• BMI of 27 or above, or
• BMI of 25 or above with a weight-related health condition

A prescriber will assess your full medical history before treatment is approved.

Wegovy tablets are not suitable for everyone. You should not take them if any of the following apply:

Medical conditions

• Personal or family history of medullary thyroid carcinoma (a type of thyroid cancer)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Severe kidney or liver disease
• Diabetic retinopathy
• Severe gastrointestinal disease, including gastroparesis
• Allergy to semaglutide or any ingredient in the tablet

Pregnancy and breastfeeding

• Pregnant, planning pregnancy, or breastfeeding

Other medications

• Currently taking other GLP-1 medicines (Wegovy injections, Ozempic, Rybelsus)
• Taking insulin or certain diabetes medications (dose adjustments may be required under medical supervision)

Age

• Under 18 years of age

If you're unsure whether Wegovy tablets are suitable for you, our prescribers can assess your circumstances through a short online consultation.

The most common side effects affect the digestive system and are usually most noticeable when starting treatment or moving to a higher dose. Gradual dose titration is specifically designed to reduce both the frequency and severity of these effects.

Common side effects include nausea, diarrhoea, vomiting, constipation, and stomach discomfort. These are typically temporary and improve as your body adjusts to the medication.

Contact your prescriber if side effects are persistent or severe. Full information is included in the patient information leaflet supplied with your medication.

Read More

Wegovy tablets are available from Pharmacy Planet from as low as £95 per month. Pricing is based on the dose prescribed, with costs typically increasing as you titrate through the schedule.

There are no hidden consultation fees. Complete your online consultation and, if suitable, your prescription and medication are arranged through the same simple process.

Wegovy tablets are not currently available on the NHS. If NICE recommends them in future, access would likely follow similar criteria to Wegovy injections — requiring referral through a specialist weight management service, strict BMI thresholds, and evidence that other weight loss approaches have already been tried.

NHS waiting lists for these services are long, and many clinically eligible patients wait months or years. Private prescribing through Pharmacy Planet means no GP referral, no waiting list, and a consultation you can complete today.